ASH 2024

• OUTCOME OF PATIENTS WITH MANTLE CELL LYMPHOMA AFTER FAILURE OF ANTI-CD19 CAR T-CELL THERAPY: A DESCAR-T STUDY BY LYSA GROUP.

Marion Aymard

• OUTCOMES OF PATIENTS WITH HODGKIN LYMPHOMA RECEIVING BRENTUXIMAB VEDOTIN (BV) AS MAINTENANCE THERAPY AFTER ASCT ACCORDING TO PREVIOUS EXPOSURE TO BV. A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY IN COLLABORATION WITH GELTAMO, FIL, LYSARC, AND TURKISH LYMPHOMA GROUP

Maria Carmen & Martinez Munoz

• HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME AFTER ANTI-CD19 CAR T-CELLS FOR B-CELL LYMPHOMA AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A LYSA, SFCE AND GRAALL STUDY FROM THE DESCAR-T REGISTRY.

Nicolas Gower

• ULTRASENSITIVE CIRCULATING TUMOR DNA MRD STATUS PREDICTS TREATMENT FAILURE & COMPLEMENTS PET/CT THROUGHOUT TREATMENT FOR EARLY AND ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA.

Jan Boegeholz & Cedric Rossi

• OUTCOMES OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS TREATED WITH A PET-GUIDED STRATEGY IN THE RANDOMIZED PHASE 3 GAINED STUDY CONDUCTED BY LYSA.

Vincent Camus

• SENIOR-IPI: AN EASILY APPLICABLE AND MEANINGFUL PROGNOSTIC INDEX FOR FIRST-LINE LBCL PATIENTS OLDER THAN 80 YEARS TREATED WITH AGE-ADAPTED IMMUNOCHEMOTHERAPY.

Sydney Dubois

• IBRUTINIB, VENETOCLAX PLUS CD20 MONOCLONAL AB PROVIDES VERY HIGH MRD NEGATIVITY IN PREVIOUSLY UNTREATED MCL PATIENTS, INITIAL RESULTS OF OASIS II, A RANDOMIZED PHASE 2 TRIAL.

Steven Le Gouill

• A SINGLE CELL ATLAS OF FOLLICULAR LYMPHOMA ACROSS CLINICAL STAGES DEFINES TUMOR B CELL ARCHETYPES, IMMUNE MICROENVIRONMENT HETEROGENEITY AND NOVEL CELL STATES ASSOCIATED WITH HIGH-RISK FL.

Sandrine Roulland

• DISTINCT MOLECULAR ABERRATIONS OF CLASSIC HODGKIN LYMPHOMA IN OLDER ADULTS IDENTIFIED BY COMPREHENSIVE GENOMIC PROFILING.

Cedric Rossi

• PREDICTIVE POWER OF EARLY, SEQUENTIAL MINIMAL RESIDUAL DISEASE AND FLUORINE-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY MONITORING IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY.

Mary Callanan

• A REAL-WORLD WEIGHTED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA AGED 75 YEARS AND OLDER : A LYSA STUDY FROM THE DESCAR-T REGISTRY.

Pierre Bories

• CAR T-CELLS TREATMENT FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IS EFFECTIVE AND SAFE IN PEOPLE LIVING WITH HIV (PLWH): A LYSA STUDY FROM THE DESCAR-T REGISTRY.

Michele Clerico

• FRONTLINE R-CHOP AND BR HAVE SIMILAR OUTCOMES BY SUVMAX IN FOLLICULAR LYMPHOMA.

Patrizia Mondello

• VALEMETOSTAT MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: PRIMARY RESULTS OF THE PHASE 2 VALYM STUDY FROM THE LYSA.

Emmanuel Bachy

• CIRCULATING TUMOR DNA FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA GENOTYPING: A PROSPECTIVE MULTICENTER STUDY.

Vincent Camus

• ABERRANT CYTOPLASMIC EXPRESSION OF P16 IS A NEW STRONG PROGNOSTIC MARKER IN YOUNG MCL PATIENTS TREATED BY FRONTLINE CYTARABINE-BASED IMMUNOCHEMOTHERAPY, A STUDY FROM THE LYSA GROUP, NORDIC LYMPHOMA GROUP AND THE EUROPEAN MCL NETWORK.

Yannick Le Bris

• OUTCOMES OF PATIENTS TREATED WITH CONSOLIDATIVE BRENTUXIMAB VEDOTIN AFTER TRANSPLANT FOR HODGKIN LYMPHOMA AT HIGH RISK OF PROGRESSION OR RELAPSE: AN INNOVATIVE COMPARATIVE ANALYSIS BASED ON PROPENSITY SCORE WEIGHTING FROM PATIENTS INCLUDED IN 4 LYSA-COHORTS.

Amira Marouf

• LONG-TERM FOLLOW-UP STUDY OF PATIENTS AGED 80 YEARS OR OLDER TREATED BY ATTENUATED CHEMOTHERAPY MINI-CHOP PLUS ANTI-CD20 FOR DLBCL, UPDATE OF THE LNH03-7B AND LNH09-7B LYSA TRIALS.

Jean-Marie Michot

• HEALTH-RELATED QUALITY OF LIFE AFTER AXI-CEL AS A SECOND-LINE THERAPY IN PATIENTS WITH HIGH-RISK RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: RESULTS OF THE ALYCANTE PHASE II TRIAL.

Roch Houot

• PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN MULTIPLE MYELOMA PATIENTS TREATED WITH IDE-CEL CAR-T CELL THERAPY : PRELIMINARY RESULTS OF A REAL-WORLD IFM STUDY FROM THE DESCAR-T REGISTRY (CAR MY PET)

Bertrand Arnulf